← Back to Screener
Journey Medical Corporation Common Stock (DERM)
Price$5.17
Favorite Metrics
Price vs S&P 500 (26W)-33.51%
Price vs S&P 500 (4W)-31.38%
Market Capitalization$144.85M
All Metrics
Book Value / Share (Quarterly)$1.17
P/TBV (Annual)49.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.66%
Cash Flow / Share (Quarterly)$-0.46
Price vs S&P 500 (YTD)-33.90%
Gross Margin (TTM)66.17%
Net Profit Margin (TTM)-18.48%
EPS (TTM)$-0.48
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$-0.48
Revenue Growth (5Y)6.79%
EPS (Annual)$-0.47
ROI (Annual)-20.01%
Gross Margin (Annual)66.17%
Net Profit Margin (5Y Avg)-31.88%
Cash / Share (Quarterly)$0.89
Revenue Growth QoQ (YoY)18.05%
ROA (Last FY)-12.08%
Revenue Growth TTM (YoY)10.20%
EBITD / Share (TTM)$-0.16
ROE (5Y Avg)-81.41%
Operating Margin (TTM)-13.21%
Cash Flow / Share (Annual)$-0.46
P/B Ratio4.55x
P/B Ratio (Quarterly)6.57x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.36x
Net Interest Coverage (TTM)-2.55x
ROA (TTM)-13.22%
EV / EBITDA (TTM)68.76x
EPS Incl Extra (Annual)$-0.47
Current Ratio (Annual)1.79x
Quick Ratio (Quarterly)1.44x
3-Month Avg Trading Volume0.18M
52-Week Price Return-14.65%
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$0.16
P/S Ratio (Annual)2.34x
Asset Turnover (Annual)0.65x
52-Week High$9.55
Operating Margin (5Y Avg)-26.16%
EPS Excl Extra (Annual)$-0.47
CapEx CAGR (5Y)44.27%
26-Week Price Return-29.52%
Quick Ratio (Annual)1.44x
13-Week Price Return-31.52%
Total Debt / Equity (Annual)0.79x
Current Ratio (Quarterly)1.79x
Enterprise Value$146.04
Revenue / Share Growth (5Y)-1.39%
Asset Turnover (TTM)0.72x
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)1.74x
Pretax Margin (Annual)-18.38%
Cash / Share (Annual)$0.89
3-Month Return Std Dev81.89%
Gross Margin (5Y Avg)59.32%
Net Income / Employee (TTM)$-0
ROE (Last FY)-35.89%
Net Interest Coverage (Annual)-2.55x
EPS Basic Excl Extra (Annual)$-0.47
P/FCF (TTM)6.38x
Receivables Turnover (TTM)3.09x
Total Debt / Equity (Quarterly)0.79x
EPS Incl Extra (TTM)$-0.48
Receivables Turnover (Annual)3.09x
ROI (TTM)-22.97%
P/S Ratio (TTM)2.34x
Pretax Margin (5Y Avg)-31.25%
Revenue / Share (Annual)$2.52
Tangible BV / Share (Annual)$0.16
Forward P/E71.31x
Price vs S&P 500 (52W)-44.48%
Year-to-Date Return-31.26%
5-Day Price Return2.12%
EPS Normalized (Annual)$-0.47
ROA (5Y Avg)-21.75%
Net Profit Margin (Annual)-18.48%
Month-to-Date Return13.01%
Cash Flow / Share (TTM)$0.07
EBITD / Share (Annual)$-0.16
Operating Margin (Annual)-13.21%
LT Debt / Equity (Annual)0.79x
ROI (5Y Avg)-43.38%
LT Debt / Equity (Quarterly)0.79x
EPS Basic Excl Extra (TTM)$-0.48
P/TBV (Quarterly)49.26x
P/B Ratio (Annual)6.57x
Inventory Turnover (TTM)1.74x
Pretax Margin (TTM)-18.38%
Book Value / Share (Annual)$1.17
Price vs S&P 500 (13W)-32.21%
Beta1.06x
P/FCF (Annual)603.55x
Revenue / Share (TTM)$2.28
ROE (TTM)-46.40%
52-Week Low$4.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DERMJourney Medical Corporation Common Stock | 2.34x | 10.20% | 66.17% | — | $5.17 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Journey Medical Corp commercializes a portfolio of eight FDA-approved prescription drugs for dermatological conditions in the U.S. market. Key products include Qbrexza, Accutane, Amzeeq, and Exelderm, which treat various skin-related medical conditions. The company focuses on dermatological treatments for healthcare providers and patients.